NL0010391025
NL0010391025
PHARMING GROUP
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 620.3M EUR | 850.75M EUR | 1.01B EUR | 1B EUR |
Enterprise Value | 575.31M EUR | 805.77M EUR | 1.08B EUR | 971.07M EUR |
Valuation Multiples | ||||
Trailing P/E | 87.64x | 91.75x | 82.15x | 57.04x |
Forward P/E | 35.08x | -- | -- | -- |
Price to Sales | 1.69x | 2.32x | 2.74x | 3.37x |
Price to Book | 2.67x | 3.15x | 3.77x | 3.61x |
EV/Revenue | 1.57x | 2.2x | 2.91x | 3.27x |
EV/EBITDA | 17.5x | 18.89x | 24.65x | 22.78x |
Price to FCF (P/FCF) | 16.46x | 24.75x | 18.18x | 18.53x |
EV/FCF | 15.27x | 23.45x | 19.32x | 17.98x |
FCF Yield | 6.08% | 4.04% | 5.5% | 5.4% |